Keruo Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keruo Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Baoxin Qian
Huiying Medical Technology, Bejing, China
1 shared publication Chuanfeng Liu
Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
1 shared publication- Dengyi Duan
Department of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
1 shared publication - Di Yin
Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
1 shared publication - Gang Li
Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, China
1 shared publication - Guixin Wang
Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
1 shared publication
Latest Publications
- Open Access
- 12 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 443
Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Pathologic T3a Upstaging in Clinical T1 RCC
Background/Objectives: To develop a nomogram for the preoperative prediction of pathologic T3a (pT3a) upstaging in patients with clinical T1(cT1) renal cell carcinoma (RCC). Methods: A total of 169 cT1 patients with RCC with preoperative contrast-enhanced CT (CECT) and clinical data were enrolled in this study. Afterwards, the sample was split randomly into training and testing sets in a 7:3 ratio. Radiomics features were extracted and selected from the whole primary tumor on CECT images to develop radiomics signatures. The nomogram was constructed using the obtained radiomics signature and clinical risk factors. The predictive performance of different models was evaluated and visualized using receiver operator characteristic (ROC) curves. Results: In total, 26 radiomics features were selected for the radiomics signature construction. The radiomics signature yielded area under the curve (AUC) values of 0.945 and 0.873 in the training and testing sets, respectively. The nomogram integrating radiomics signature and predictive clinical factors, including tumor size and neutrophil–lymphocyte ratio (NLR), achieved higher predictive performance in the training [AUC, 0.958; 95% confidence interval (CI): 0.921, 0.995] and testing (AUC, 0.913; 95% CI: 0.814, 1.000) sets. Good calibration was achieved for the nomogram in both the training and testing sets (Brier score = 0.082 and 0.098). Decision curve analysis (DCA) demonstrated that the nomogram was clinically useful in predicting pT3a upstaging, with a corresponding net benefit of 0.378. Conclusions: The proposed nomogram can preoperatively predict pT3a upstaging in cT1 RCC and serve as a non-invasive imaging marker to guide individualized treatment.
- 12 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 443
Open AccessContrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Pathologic T3a Upstaging in Clinical T1 RCC
Background/Objectives: To develop a nomogram for the preoperative prediction of pathologic T3a (pT3a) upstaging in patients with clinical T1(cT1) renal cell carcinoma (RCC). Methods: A total of 169 cT1 patients with RCC with preoperative contrast-enhanced CT (CECT) and clinical data were enrolled in this study. Afterwards, the sample was split randomly into training and testing sets in a 7:3 ratio. Radiomics features were extracted and selected from the whole primary tumor on CECT images to develop radiomics signatures. The nomogram was constructed using the obtained radiomics signature and clinical risk factors. The predictive performance of different models was evaluated and visualized using receiver operator characteristic (ROC) curves. Results: In total, 26 radiomics features were selected for the radiomics signature construction. The radiomics signature yielded area under the curve (AUC) values of 0.945 and 0.873 in the training and testing sets, respectively. The nomogram integrating radiomics signature and predictive clinical factors, including tumor size and neutrophil–lymphocyte ratio (NLR), achieved higher predictive performance in the training [AUC, 0.958; 95% confidence interval (CI): 0.921, 0.995] and testing (AUC, 0.913; 95% CI: 0.814, 1.000) sets. Good calibration was achieved for the nomogram in both the training and testing sets (Brier score = 0.082 and 0.098). Decision curve analysis (DCA) demonstrated that the nomogram was clinically useful in predicting pT3a upstaging, with a corresponding net benefit of 0.378. Conclusions: The proposed nomogram can preoperatively predict pT3a upstaging in cT1 RCC and serve as a non-invasive imaging marker to guide individualized treatment.